the aid library

LIST OPTIONS

Filter

8172

Sort by:

Direction:

Download (178)

View PDF (211)

Out with it - HIV and Other Sexual Health Considerations for Young Men Who Have Sex with Men

G. Ayala; R. Baggaley; B. Konstantinov; et al. MPact: Global Action for Gay Men’s Health and Rights; World Health Organization; UNDP; UNFPA; (2018) C_WHO

Technical Brief

Download (155)

View PDF (192)

Guideline: Adherence to antiretroviral therapy in adolescents and young adults (expanded version)

L. Fairlie; L. Jankelowitz; H. Ronald; et al. Southern African HIV Clinicians Society; Right to Care (Training Health Seriously) (2017) C2

Recommendations, resources and references A publication of the Southern African HIV Clinicians Society

Download (305)

View PDF (475)

Advancement of the UN CRPD through the 2030 Agenda Towards Implementation in Latin America

International Disability Alliance UNICEF; UN Partnership to Promote Rights of People with Disabilites (2016)

Conference Report Sao Paulo, Brazil 22-24 October 2015

Download (110)

View PDF (136)

Male engagement in the HIV response - a Platform for Action

UNAIDS (Joint United Nations Programme on HIVAIDS); IPPF International Planned Parenthood Federation; Sonke gender Justice (HIV (2016) C2

UNAIDS 2016 / Meeting Report

Download (413)

View PDF (630)

Evaluation of UNFPA support to the prevention, response to and elimination of gender-based violence, and harmful practices (2012-2017)

UNFPA; Ministry of Health and Family Welfare, Government of India; National Human Rights Commission (2017) C1

Download (780)

View PDF (1249)

Problem Management Plus (PM+)
recommended

World Health Organization WHO (2016) C_WHO

Individual psychological help for adults impaired by distress in communities exposed to adversity. The manual describes a scalable psychological intervention called Problem Management Plus (PM+) for adults impaired by distress in communities who are exposed to adversity. Aspects of Cognitive Behavi... more

Download (74)

View PDF (529)

A double dose of inequality; Pharma companies and the Covid-19 vaccines crisis

Amnesty International (2022) C2

22 Sept. 2021 The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisi... more

Download (127)

View PDF (167)

Legal Guide for the Protection of Venezuelan Refugees and Migrants against Forced Evictions

R4V (2021) CC

The right to adequate housing, despite having been recognized by multiple international instruments, continues to be a human right that is consistently violated. Around 2O% of the world's population do not have adequate housing . In Latin America, informal settlements generally lack the conditions r... more

Download (79)

View PDF (123)

Europe at a Crossroads - Dos and don’ts for authorities when responding to the Covid-19 pandemic

OCHA; Reliefweb; Amnesty International (2020) C2

Human rights must be at the centre of all prevention, preparedness, containment and treatment efforts from the start, in order to best protect public health and support the groups and people who are most at risk. States have an obligation to protect and guarantee everyone the right to the highest at... more

Download (365)

View PDF (595)

HIV, HCV, TB and harm reduction in prisons

G. Sander Harm Reduction International; European Union (2016) C1

Human Rights, Minimum Standards and Monitoring at the European and International Levels

Download (193)

View PDF (167)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (195)

View PDF (264)

World Drug Report 2019 Booklet 5 Drugs and the environment

United Nations Office on Drug and Crime UNODC (2022) C2

The booklet starts with a general overview of how illicit drugs and the environment are linked within the bigger picture of the Sustainable Development Goals, climate change and environmental sustainability. It highlights direct and indirect linkages and gives examples of the significant local and i... more

Download (151)

View PDF (177)

Namibia: “We don’t feel well treated”: Tuberculosis and the Indigenous San peoples of Namibia

Amnesty International (2021) C1

Tuberculosis (TB) is an infectious disease that usually affects the lungs, though it can affect any organ in the body. It can develop when bacteria spread through droplets in the air. TB can be fatal, but in many cases, TB is preventable and treatable. This report examines the human rights impact of... more

Download (146)

View PDF (221)

Communities at the Centre

UNAIDS (2019) C2

Defending Rights Breaking Barriers Reaching People with HIV Services Global Aids Update 2019

Download (135)

View PDF (179)

ECRI Report on Germany

ECRI (2019) CC

The European Commission against Racism and Intolerance (ECRI) was established by the Council of Europe. It is an independent body which ensures respect for human rights in the fight against racism, discrimination (based on "race", ethnic/national origin, colour, nationality, religion, language, sexu... more

Download (146)

View PDF (263)

The Paris Principles: Principles and Guidelines on Children associated with Armed Forces and Armed Groups

United Nations Children's Fund (UNICEF) (2007) C1

The recruitment and use of children violates their rights and causes them physical, developmental, emotional, mental, and spiritual harm. The impact on their mental and physical well-being breaches the most fundamental human rights and represents a grave threat to durable peace and sustainable deve... more

Download (39)

View PDF (42)

Sexual, reproductive, maternal, newborn, child and adolescent health: report on the 2023 policy survey

World Health Organisation (WHO) (2024) C_WHO

Evidence- and rights-based national policies, guidelines and legislation play a key role in improving sexual, reproductive, maternal, newborn, child and adolescent health (SRMNCAH), framing the enabling environment for equitable provision and accessibility of quality services. The SRMNCAH policy sur... more

Download (262)

View PDF (357)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (157)

View PDF (244)

Laboratory testing for the monkeypox virus
recommended

World Health Organization (WHO) (2022) C_WHO

Any individual that meets the suspected case definition of monkeypox should be offered testing in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. Confirmation of monkeypox virus infection is based on nucleic acid amplification testing (NAAT), usi... more

Problem Management Plus (PM+) recommended

Laboratory testing for the monkeypox virus recommended

Problem Management Plus (PM+)
recommended

Laboratory testing for the monkeypox virus
recommended